Airway Therapeutics is a biotechnology company focused on developing novel biologics to address respiratory and inflammatory diseases. The company operates in the healthcare sector, specifically targeting conditions such as bronchopulmonary dysplasia (BPD) and other serious respiratory diseases. Airway Therapeutics' core product, AT-100, is a recombinant human protein engineered to reduce inflammation and infection while modulating the immune response. This product aims to break the cycle of injury and inflammation, offering a potential therapeutic solution for conditions exacerbated by ventilation and infection, particularly in very preterm infants.

The company serves a specialized market, primarily targeting healthcare providers, hospitals, and research institutions involved in neonatal and respiratory care. Airway Therapeutics' business model revolves around research and development, clinical trials, and eventual commercialization of its biologic therapies. Revenue generation is expected through product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies.

Airway Therapeutics has secured significant funding through multiple rounds of financing, including Series B and Series C rounds, to advance its preclinical and clinical research programs. The company is also collaborating with organizations like the Celonic Group to produce AT-100, positioning it as a promising candidate for treating novel coronavirus infections.

Keywords: biologics, respiratory diseases, inflammation, infection, bronchopulmonary dysplasia, preterm infants, AT-100, healthcare, biotechnology, clinical trials.